TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25071414
Drug: Structured oral
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured oral information in addition to standard care, covering procedural, sensory, and coping information, and individualized fears and questions; administered in a single episode lasting 10-15 minutes.
Study: 25071414
Drug: Non-specific episodic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific episodic conversation of similar length in addition to standard care; administered in a single episode lasting 10-15 minutes.
Study: 17370153
Drug: Optimal drug
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal drug therapy for heart failure
Study: 15730636
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg, twice daily for 5 days
Study: 15730636
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (symptom relief medicine)
Study: 11777221
Drug: Clariscan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clariscan 0.75 mg Fe/kg body weight
Study: 11777221
Drug: Clariscan 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clariscan 2 mg Fe/kg body weight
Study: 11777221
Drug: Clariscan 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clariscan 5 mg Fe/kg body weight
Study: 9133758
Drug: Sertraline (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (n = 56)
Study: 29868853
Drug: Verinurad combined
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad combined with febuxostat (2.5-10 mg with febuxostat 10, 20, 40 mg)
Study: 29868853
Drug: Verinurad alone
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad alone (2.5-15 mg)
Study: 29868853
Drug: Febuxostat alone
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat alone (10, 20, 40 mg)
Study: 29868853
Drug: Benzbromarone alone
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone alone (50 mg)
Study: 25338798
Drug: Periodontal-pulp combined
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal-pulp combined therapy
Study: 25338798
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy (Control)
Study: 27893539
Drug: Radiofrequency (RF)
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency (RF) treatment
Study: 15389228
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) 500 mg immediately before the procedure
Study: 7925519
Drug: Nifedipine CC
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine CC (40 mg oral dose)
Study: 63748
Drug: sulphafurazole (sulfisoxazole),
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphafurazole (sulfisoxazole), 500 mg orally q.i.d. for 10 days
Study: 63748
Drug: aminocyclitols (streptomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminocyclitols (streptomycin or spectinomycin), 2 g intramuscularly for 1 to 3 doses at 12 h intervals
Study: 63748
Drug: C+U+ N.G.U.
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+U+ N.G.U.
Study: 30661559
Drug: Naturalistic cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturalistic cognitive behavioral therapy (CBT)
Study: 23568940
Drug: Trust in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trust in vaccine safety
Study: 19828711
Drug: Iron-fortified milk
Normalized name: iron succinyl milk protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified milk (1.5 mg iron/100 g prepared milk)
Study: 19828711
Drug: Red meat
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red meat (approximately 2.6 mg iron from red meat dishes daily)
Study: 19828711
Drug: Control (nonfortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nonfortified milk with 0.01 mg iron/100 g prepared milk)
Study: 10423226
Drug: Brand N
Normalized name: Select Brand Naproxen Sodium 220mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand N (RMP + INH tablet)
Study: 10423226
Drug: Brand R
Normalized name: von Willebrand receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand R (reference brand R, RMP + INH tablet)
Study: 10423226
Drug: Brand L
Normalized name: Select Brand Lancets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand L (RMP + INH capsule)
Study: 92091
Drug: Megestrol (Megace,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol (Megace, 120 mg./day)
Study: 23471856
Drug: Subcutaneous skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous skin elevation
Study: 19124628
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 (1000 mcg sublingual) for 6 months
Study: 15151491
Drug: Individualised supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised supervised physiotherapy treatment
Study: 15151491
Drug: Individualised physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualised physiotherapy treatment
Study: 11481625
Drug: peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2b (0.5, 1.0, or 1.5 microg/kg, once-weekly)
Study: 11481625
Drug: peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2b (all doses)
Study: 11481625
Drug: interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: interferon alfa-2b (3 MIU, three-times-weekly)
Study: 9494998
Drug: Intravesical installation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical installation of 30 mg capsaicin in 100 ml of 30% alcohol
Study: 9494998
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml 30% alcohol alone (control group)
Study: 31329189
Drug: Complex non-drug
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex non-drug programs including exercise therapy, mineral water, multivitamins, minerals, and physiotherapy (vibrotherapy, chromotherapy, melotherapy, aromatherapy, aeroionotherapy)
Study: 31329189
Drug: Complex non-drug
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex non-drug programs including vibrotherapy, chromotherapy, melotherapy, aromatherapy, and aeroionotherapy
Study: 19796594
Drug: Bristled brush
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bristled brush pre-treatment
Study: 16839845
Drug: ACTH1-24 1
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH1-24 1 mg IM, daily for 4 days
Study: 16839845
Drug: Cortisol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol 150 mg ID (50 mg tid) daily for 4 days
Study: 15486187
Drug: Doxorubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m² q3wks)
Study: 15486187
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m² q3wks)
Study: 7680995
Drug: 2.9 g
Normalized name: ZINC OXIDE 12.9 g in 100 g TOPICAL LOTION [UV Skin Recovery SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.9 g piracetam
Study: 7680995
Drug: 4.8 g
Normalized name: ALCOHOL 74.8 g in 100 g TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g piracetam
Study: 7680995
Drug: 9.6 g
Normalized name: PETROLATUM 99.6 g in 100 g TOPICAL JELLY [Petrolatum Jelly]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.6 g piracetam
Study: 25182161
Drug: Diastolic blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diastolic blood pressure lowering treatment
Study: 18543037
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with Epidoxorubicin, Etoposide, and Cisplatin (EEP)
Study: 18543037
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with postoperative chemotherapy alone (previously studied controls)
Study: 12744488
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day enalapril for 5 days
Study: 12744488
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 20 mg enalapril 2 h before LPS infusion
Study: 11223318
Drug: Effective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective treatment included in trial protocol
Study: 9551704
Drug: Valsartan alone
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan alone (160 mg)
Study: 9551704
Drug: Cimetidine alone
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine alone (800 mg)
Study: 29065953
Drug: Lemborexant (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant (1, 2.5, 5, 10, 15, 25 mg)
Study: 29065953
Drug: Lemborexant (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant (doses > 1 mg)
Study: 29065953
Drug: Lemborexant (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant (2.5-10 mg)
Study: 25495490
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus ovarian suppression (in patients who received prior chemotherapy)
Study: 25495490
Drug: Tamoxifen (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (in patients who received prior chemotherapy)
Study: 16489082
Drug: Concurrent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent docetaxel plus vaccine
Study: 9148018
Drug: Vaccine alone
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine alone
Study: 11202309
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with multimodal therapy including chemotherapy
Study: 7918155
Drug: rhSOD (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhSOD (200 mg intravenously during surgery)
Study: 29457429
Drug: Stiletto needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stiletto needle treatment once a week for 2 weeks
Study: 29457429
Drug: Needle-knife treatment
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-knife treatment once a week for 2 weeks
Study: 29457429
Drug: Voltaren treatment
Normalized name: Voltarene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voltaren treatment (votalin emulsion smearing 3 to 5 cm on painful area of knee joint, three times a day for 2 weeks)
Study: 21490326
Drug: Intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fat emulsion
Study: 12883232
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg/d for 14 days
Study: 10868320
Drug: ECT x
Normalized name: BRIEF,SELECT XX-LARGE #2608
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT x 2 (twice weekly)
Study: 10868320
Drug: ECT x
Normalized name: BRIEF,SELECT XX-LARGE #2608
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT x 3 (three times weekly)
Study: 2870753
Drug: Active neuroleptic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active neuroleptic medication
Study: 23364781
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with 1 mL kg(‐1) 0.25% levobupivacaine
Study: 14966922
Drug: Erythropoietin (20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (20,000 IU Epoetin alfa subcutaneously on days 0, 4, and 6) plus iron (100 mg im on days 1-6)
Study: 11347747
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 g three times per day)
Study: 2889679
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg cinolazepam
Study: 30671869
Drug: Brexpiprazole 2–4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 2–4 mg/day
Study: 30671869
Drug: Brexpiprazole 1–4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 1–4 mg/day (maintenance treatment)
Study: 28494892
Drug: Continuous TAP
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous TAP block using ultrasound-guidance with 0.2% ropivacaine at a basal rate of 3mL/h, bolus dose of 4mL, and a lockout interval of 30min for 48h postoperatively
Study: 24458265
Drug: Cold water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold water immersion therapy
Study: 24458265
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cold water immersion therapy)
Study: 16972117
Drug: Methylphenidate combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate combined with 10 weeks of multimodal behavior therapy
Study: 12660880
Drug: Thiazolidinedione treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinedione treatment
Study: 2149281
Drug: Toremifene (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (oral doses of 10-480 mg per day for one or five days)
Study: 30058726
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily oral 100 mg KH176 for 28 days
Study: 28134225
Drug: LABA (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA (long-acting beta-agonist) such as indacaterol, vilanterol, or olodaterol used once a day.
Study: 28134225
Drug: LAMA (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMA (long-acting muscarinic antagonist) such as tiotropium, glycopyrronium, aclidinium, or umeclidinium.
Study: 28134225
Drug: Combined preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparations of LAMA-LABA.
Study: 28134225
Drug: MABA (muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABA (muscarinic antagonist and β2 agonist).
Study: 20939799
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide intravitreal implant (Retisert)
Study: 20939799
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide intravitreal implant (Iluvien)
Study: 20939799
Drug: Combination photocoagulation
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination photocoagulation and pharmacotherapy
Study: 17595894
Drug: Digox 0.25
Normalized name: Digox 0.25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digox 0.25 mg tablet from Pharlab Ind. Ltd., Brazil
Study: 17595894
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg tablet from Laboratório Glaxo SmithKline, Brazil
Study: 2528440
Drug: Etodolac (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (600 mg/day)
Study: 31730814
Drug: Anti-viral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-viral therapy
Study: 28517974
Drug: DHA +
Normalized name: PNV-DHA + Docusate Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA + aspirin therapy (2 g DHA + 81 mg aspirin daily)
Study: 28517974
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo capsules)
Study: 25867448
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (CBT and SST)
Study: 22663759
Drug: Attendance education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attendance education during monthly visits at the center
Study: 12686509
Drug: Duodenal acid
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal acid infusion (0.1 N HCl)
Study: 8678498
Drug: 5-FU (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (500-750 mg/body) and LV (30 mg/body) for 5 days
Study: 8678498
Drug: 5-FU (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (500-750 mg/body) and LV (30 mg/body) plus cisplatin (10 mg/body)
Study: 1872778
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose monophasic combined oral contraceptive
Study: 1872778
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose danazol
Study: 25140396
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/day (R10)
Study: 25140396
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg/day (R40)
Study: 17661764
Drug: Octreotide (Sandostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (Sandostatin LAR 20 mg i.m.)
Study: 15679243
Drug: Concomitant cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant cisplatin-based chemotherapy with radiotherapy
Study: 15679243
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin-5FU) followed by local treatment
Study: 10737578
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection in the internal anal sphincter on each side of the posterior midline (group I)
Study: 10737578
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection in the internal anal sphincter on each side of the anterior midline (group II)
Study: 8725483
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (medication)
Study: 12674130
Drug: Estrogen-progestin hormone
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progestin hormone replacement therapy
Study: 1328978
Drug: Women who
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who had never taken hormone replacement therapy
Study: 1328978
Drug: Women who
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who had ever taken hormone replacement therapy
Study: 21159397
Drug: Treatment times
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment times
Study: 15730803
Drug: Normal internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal internal medicine treatments (Control)
Study: 7931752
Drug: Physicians prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physicians prescribing medications
Study: 3652706
Drug: Surfactant (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (2 ml/kg; phospholipid concentration, 100 mg/ml) administered via naso-endotracheal tube during standardized ventilatory maneuvers
Study: 28865459
Drug: Indigo naturalis
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigo naturalis ointment (n = 16)
Study: 19688315
Drug: Qingre Buyi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingre Buyi Decoction (QBD) plus conventional treatment
Study: 14742998
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1 g every 8 hr) from days 15 to 100 after transplantation
Study: 14742998
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (6 mg/kg once per day on Monday‐Friday of each week) from days 15 to 100 after transplantation
Study: 2404346
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg at night)
Study: 29773490
Drug: VSM arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VSM arm (study website with vaccine information and social media components)
Study: 29773490
Drug: VI arm
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VI arm (website with vaccine information only)
Study: 29773490
Drug: Self-efficacy around
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-efficacy around vaccine decision making
Study: 24415868
Drug: CIGB-230 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIGB-230 (6 doses as late add-on)
Study: 23111478
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) therapy for 6 months
Study: 18403419
Drug: Flare-up GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flare-up GnRH agonist protocol
Study: 12459133
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education (verbal and written information on generic vs brand-name drugs)
Study: 8583018
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine rinse, 18 mg per rinse
Study: 8583018
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine rinse, 20 mg per rinse
Study: 2127178
Drug: Glibenclamid‐ratiopharm (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamid‐ratiopharm (treatment A)
Study: 2127178
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (treatment B)
Study: 6117901
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prostacyclin (PGI2) and heparin